Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

NCT04023552 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

8323

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Disease and Lipoprotein(a)

Interventions

DRUG: TQJ230
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals